PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical tr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda, Murali Ramachandra
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a

Ejemplares similares